Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life

Authors Roberta Annicchiarico, Alessia Federici, Carla Pettenati, Carlo Caltagirone

Published 15 January 2008 Volume 2007:3(6) Pages 1113—1123

Roberta Annicchiarico1, Alessia Federici1, Carla Pettenati2, Carlo Caltagirone3
1I.R.C.C.S. Fondazione Santa Lucia, Rome, Italy; 2Centro Alzheimer, Ospedale di Passirana di Rho, Rho, Milan, Italy; 3Dipartimento Neurologia Università “Tor Vergata” di Roma, I.R.C.C.S. Fondazione Santa Lucia, Rome, Italy
Abstract: Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive and functional abilities associated with various behavioral disturbances. Its impact on public health and society as a whole is devastating. Slowing of the cognitive impairment, and improvements in disease duration, self-sufficiency and behavioral disturbances represent the best outcomes of pharmacologic therapy. Cholinesterase inhibitors (ChE-I) have been shown to be effective in treating the cognitive, behavioral, and functional deficits of AD. Rivastigmine is a dual inhibitor of both acetylcholine esterase (AChE) and butyrylcholinesterase (BuChE), enzymes involved in the hydrolysis of acetylcholine. Although this drug has been shown to be beneficial in patients with AD, its benefits are limited and their long-term effectiveness has not been well demonstrated.
Keywords: Alzheimer’s disease, drugs, therapy

Download Article [PDF] 

Readers of this article also read:

A case of isolated adrenocorticotropic hormone deficiency: a rare but possible cause of hypercalcemia

Harano Y, Kitano A, Akiyama Y, Kotajima L, Honda K, Arioka H

International Medical Case Reports Journal 2015, 8:77-79

Published Date: 27 March 2015

Unusual case of contralateral Horner's syndrome following stellate-ganglion block: a case report and review of the literature

Amhaz HH, Manders L, Chidiac EJ, Pallekonda V, Chakrabortty S

Local and Regional Anesthesia 2013, 6:31-33

Published Date: 10 October 2013

Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm

Xie S, Pan B, Shi B, Zhang Z, Zhang X, Wang M, Zhou W

International Journal of Nanomedicine 2011, 6:2367-2374

Published Date: 18 October 2011

Anthracycline extravasation injuries: management with dexrazoxane

Karin Jordan, Timo Behlendorf, Franziska Mueller, Hans-Joachim Schmoll

Therapeutics and Clinical Risk Management 2009, 5:361-366

Published Date: 8 May 2009

Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations

Gabriele Nicolini, Nicola Scichilone, Andrea Bizzi, Alberto Papi, Leonardo M Fabbri

Therapeutics and Clinical Risk Management 2008, 4:855-864

Published Date: 10 October 2008

An “acquired” hemoglobin J variant in a sickle cell disease patient

Nawwar Swedan, Kathleen Nicol, Phylis Moder, Samir Kahwash

Therapeutics and Clinical Risk Management 2008, 4:649-652

Published Date: 6 June 2008

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

Andrew J Armstrong, Daniel J George

Therapeutics and Clinical Risk Management 2007, 3:877-883

Published Date: 15 November 2007

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

Current treatment options in the management of chronic prostatitis

Alain Jean Duclos, Chun-Te Lee, Daniel Arthur Shoskes

Therapeutics and Clinical Risk Management 2007, 3:507-512

Published Date: 15 September 2007